PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs
Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable WALTHAM, Mass. – April, 21, 2021 PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which... Read more